Bavarian Nordic's largest shareholder refuses to back a sweetened takeover offer for the Danish vaccine maker https://t.co/cMQcLSpASr ...

Core Viewpoint - Bavarian Nordic's Board of Directors maintains its recommendation for shareholders to accept the takeover offer from Innosera ApS, citing the offer as fair and attractive based on the company's fundamental value and historical share price levels [2][3]. Offer Details - The takeover offer is for all issued and outstanding shares of Bavarian Nordic, excluding treasury shares, made by Innosera ApS, which is controlled by Nordic Capital Fund XI and Permira Beteiligungsberatung GmbH [1]. - The offer period has been extended, and the offer price has been increased, prompting the Board to reiterate its recommendation [2][3]. Company Background - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [7].

Bavarian Nordic said on Wednesday a consortium led by Nordic Capital and Permira has raised its offer price for the vaccine maker to 250 Danish crowns ($38.94) after its initial bid was not accepted b... ...

Core Viewpoint - Innosera ApS has received all necessary regulatory approvals from the European Commission for its all-cash voluntary recommended public takeover offer for Bavarian Nordic A/S, with the offer period set to expire on 14 October 2025 [1][27]. Group 1: Offer Details - The offer is contingent upon the minimum acceptance condition of 75% of the shares in Bavarian Nordic, excluding treasury shares [2]. - If the remaining conditions are satisfied by the expiration date, the completion of the offer is expected to occur in mid-November 2025 [4]. - Bavarian Nordic shareholders are encouraged to accept the offer before the expiration date [3]. Group 2: Company Background - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [8].

Core Insights - Galapagos, a Belgian biotechnology company, has experienced significant volatility over the past decade, particularly following a major partnership with Gilead Sciences in 2015, which was expanded in 2019 with a $5.1 billion deal [3][4] - The company's American depositary receipts (ADRs) saw a dramatic decline from a peak of over $274 in February 2020 to below $23 in February 2025, although recent restructuring efforts have led to a recovery, with ADRs trading around $35 [4] - As part of its restructuring, Galapagos announced plans to split into two publicly traded companies, retaining the Galapagos name for its cell therapy unit and appointing Henry Gosebruch as CEO of the spinout [5] Company Developments - In May 2023, Galapagos indicated a potential change in its restructuring plan, and by July, it was considering a sale of its cell therapy business [6] - The company has reported interest from a "limited number" of potential buyers for its cell therapy business, primarily consisting of financial investors, and is currently engaged in due diligence with these parties [8] - Fully-financed, binding offers for the cell therapy business are expected within weeks, with a decision on whether to divest or pursue alternative actions to be announced by November 5, coinciding with the release of third-quarter financial results [8]

Core Viewpoint - Innosera ApS, controlled by Nordic Capital Fund XI and Permira, has extended its all-cash voluntary takeover offer for Bavarian Nordic A/S by two weeks to obtain the last outstanding regulatory approval necessary for the acquisition [1][2]. Group 1: Offer Details - The initial offer period, which began on August 26, 2025, was set to expire on September 30, 2025, but has now been extended to October 14, 2025, at 11:59 p.m. (CEST) [3][6]. - The Offeror has received regulatory approvals in several jurisdictions, including Australia, China, Saudi Arabia, Switzerland, and the United States, with the only remaining approval being from the European Union [2][5]. Group 2: Board Recommendations - Bavarian Nordic's Board of Directors has recommended that shareholders accept the Offer, and this recommendation remains unchanged despite the extension of the offer period [4][5]. Group 3: Timetable and Important Dates - The updated timetable includes the announcement of the preliminary result of the Offer on October 15, 2025, and the final result by October 20, 2025, with settlement of the offer price expected by November 11, 2025 [6][7].

Summary of GeoVax Labs Conference Call Company Overview - **Company**: GeoVax Labs (NasdaqCM:GOVX) - **Industry**: Biotechnology - **Focus**: Development of novel vaccines for infectious diseases and therapies for solid tumor cancers [1] Core Points and Arguments - **Public Health Issue**: The unmet needs of immunocompromised patients, particularly in the context of COVID-19, are significant. Current vaccines are inadequate for these populations [2][3] - **Limitations of Current Vaccines**: Existing mRNA vaccines (Pfizer, Moderna, Novavax) are first-generation and have limited breadth of protection. They require reconfiguration for new variants and have a short efficacy duration of about three to six months [3] - **Target Population**: Over 40 million individuals in the U.S. and over 400 million worldwide are at high risk due to medical conditions that impair their immune response [4] - **GeoVax's Solution**: The GEO-CM04S1 vaccine is designed to address the limitations of current vaccines, providing adequate protection for high-risk groups, including blood cancer patients and those with chronic lymphocytic leukemia [5][6] - **Clinical Trials**: Two active clinical trials are underway, showing promising immune responses that exceed those of mRNA vaccines. The trials focus on blood cancer patients who do not respond to existing vaccines [6][7] Financial Status and Plans - **Funding**: GeoVax raised funds in early July and plans to raise an additional $12 million to $15 million by the end of the year to support ongoing programs [9] - **Market Interest**: The recent acquisition of Bavarian Nordic for $3 billion has generated interest in GeoVax, although the company remains focused on advancing its programs without speculation on potential acquisitions [10] Regulatory Environment - **FDA Interaction**: The company reports minimal impact from the short-staffed FDA, maintaining active communication and progress on current programs [11] Stock Price and Investor Relations - **Stock Valuation**: Analysts suggest the stock could be valued between $5 to $12 per share, indicating it is currently undervalued. GeoVax aims to enhance transparency and communication with investors to boost stock activity and liquidity [12][13][15] Additional Notes - **Upcoming Milestones**: GeoVax has several programs advancing, including a vaccine for mpox/smallpox and therapies for solid tumors, with updates expected in the near future [7][8]

A growing list of Bavarian Nordic hareholders is pushing back against a private equity bid for the Danish vaccine maker by Nordic Capital and Permira https://t.co/XxwPWOd3oH ...

Core Viewpoint - Bavarian Nordic A/S is undergoing a voluntary public takeover offer from Innosera ApS, backed by Nordic Capital Fund XI and Permira, with the Board of Directors recommending shareholders accept the offer as it presents immediate and attractive value [1][2]. Company Overview - Bavarian Nordic has evolved into a leading vaccine company since 2018, receiving multiple unsolicited inquiries for potential takeover bids [2]. - The company specializes in innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [4]. Offer Details - The Board of Directors has conducted a thorough analysis of the takeover offer, considering the company's financials, performance, and future prospects [2]. - The offer is positioned as an opportunity for shareholders to realize immediate value, which the Board finds attractive [2]. - The Board Statement regarding the offer is available in both Danish and English, with the Danish version prevailing in case of discrepancies [2][3]. Communication and Availability - Offer-related documents, including the Board Statement, are accessible on Bavarian Nordic's website, with notifications sent to registered shareholders [3].

Core Viewpoint - Innosera ApS, controlled by Nordic Capital Fund XI and Permira, has made a voluntary all-cash takeover offer for Bavarian Nordic A/S at DKK 233.0 per share, with a revised minimum acceptance condition of 75% of shares [1][3]. Group 1: Offer Details - The takeover offer is for all issued and outstanding shares of Bavarian Nordic, excluding treasury shares [1]. - The offer document has been approved by the Danish Financial Supervisory Authority and includes an acceptance form [1]. - The initial minimum acceptance condition was over 90% but has been lowered to 75% [3]. Group 2: Shareholder Guidance - Shareholders are advised to read the Offer Document and the forthcoming Board Statement in full before making a decision [4]. - The Board of Directors will issue a statement regarding the Offer as soon as possible [2]. Group 3: Company Background - Bavarian Nordic is a global vaccine company focused on innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [7].